Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study
Jonathan I Silverberg, David Rosmarin, Thomas Bieber, Raj Chovatiya et autres
us, de, ca, cz, pl, au, hr, es, bg, gb (code pays fourni par la source)
0 citations
The Lancet